Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

14.00
-0.4400-3.05%
Post-market: 13.95-0.0500-0.36%19:49 EDT
Volume:3.04M
Turnover:42.62M
Market Cap:1.10B
PE:6.90
High:14.52
Open:14.30
Low:13.95
Close:14.44
52wk High:16.91
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:2.23
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.75
PE(LYR):7.49

Loading ...

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

GlobeNewswire
·
Jul 28

Agilent receives EU approval for PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Jul 23

PagerDuty price target raised to $8 from $7 at BofA

TIPRANKS
·
Jul 22

Pagerduty Cut to Underweight from Equal-weight by Morgan Stanley

Dow Jones
·
Jul 21

Morgan Stanley Downgrades PagerDuty to Underweight From Equalweight, Trims Price Target to $9 From $10

MT Newswires Live
·
Jul 21

Pagerduty, Inc. : Morgan Stanley Cuts to Underweight from Equal-weight

THOMSON REUTERS
·
Jul 21

PagerDuty downgraded to Underweight from Equal Weight at Morgan Stanley

TIPRANKS
·
Jul 21

Pagerduty Executive Chair Jennifer Tejada Sells USD 4.23 Million in Common Shares

Reuters
·
Jul 21

CStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation

Stock News
·
Jul 20

FDA-Approved PD-L1 Test for GI Cancers Could Be A Game Changer For Agilent Technologies (A)

Simply Wall St.
·
Jul 19

Pagerduty Director Alex Shootman Files Initial Beneficial Ownership Statement

Reuters
·
Jul 16

SKB BIO's Pivotal Drug Candidate Achieves Primary Endpoint in Phase 3 Lung Cancer Trial

Stock News
·
Jul 15

Pagerduty Names Alkami CEO Alex Shootman to Board of Directors

Reuters
·
Jul 15

Pagerduty Appoints Alex Shootman to Board of Directors

THOMSON REUTERS
·
Jul 15

Agilent's PD-L1 Companion Diagnostic Receives FDA Clearance for Esophageal and Gastric Cancer Immunotherapy Selection

Deep News
·
Jul 14

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

GlobeNewswire
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14

Truist Financial Keeps Their Buy Rating on PagerDuty (PD)

TIPRANKS
·
Jul 14

Pagerduty Names Arnaud Lagarde Vice President of EMEA

Reuters
·
Jul 14

Pagerduty Announces Arnaud Lagarde, Vice President of Emea

THOMSON REUTERS
·
Jul 14